Cargando…

Obesity is not associated with disease‐free interval, melanoma‐specific survival, or overall survival in patients with clinical stage IB‐II melanoma after SLNB

BACKGROUND AND OBJECTIVES: Clinicopathologic characteristics have prognostic value in clinical stage IB‐II patients with melanoma. Little is known about the prognostic value of obesity that has been associated with an increased risk for several cancer types and worsened prognosis after diagnosis. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deckers, Eric A., Kruijff, Schelto, Bastiaannet, Esther, van Ginkel, Robert J., Hoekstra‐Weebers, Josette E. H. M., Hoekstra, Harald J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Melanoma, Sarcoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453899/ https://www.ncbi.nlm.nih.gov/pubmed/34085291 http://dx.doi.org/10.1002/jso.26555

Ejemplares similares

The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years
por: Deckers, Eric A., et al.
Publicado: (2019)

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
por: Kruijff, S., et al.
Publicado: (2009)

The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients—Results after 1 Year
por: Damude, Samantha, et al.
Publicado: (2016)

Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival
por: Kruijff, S., et al.
Publicado: (2010)

The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years
por: Moncrieff, Marc D., et al.
Publicado: (2020)

Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma
por: de Vries, Mattijs, et al.
Publicado: (2009)

Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients
por: Faut, Marloes, et al.
Publicado: (2016)

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
por: Wevers, K. P., et al.
Publicado: (2012)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

Morbidity After Inguinal Lymph Node Dissections: It Is Time for a Change
por: Faut, Marloes, et al.
Publicado: (2016)

Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?
por: Rentroia‐Pacheco, Barbara, et al.
Publicado: (2021)

Factors associated with disease‐free and abdominal recurrence‐free survival in abdominopelvic and retroperitoneal sarcomas
por: Bredbeck, Brooke C., et al.
Publicado: (2022)

Survival and the Sentinel Lymph Node in Melanoma
por: Faries, Mark
Publicado: (2009)

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma
por: Marsh, Katherine M., et al.
Publicado: (2022)

External validation and adaptation of a dynamic prediction model for patients with high‐grade extremity soft tissue sarcoma
por: Rueten‐Budde, Anja J., et al.
Publicado: (2020)

Outcome after treatment for sebaceous carcinoma: A multicenter study
por: In 't Veld, Eva Huis, et al.
Publicado: (2022)

Lymphatic Drainage Patterns from Melanomas on the Shoulder or Upper Trunk to Cervical Lymph Nodes and Implications for the Extent of Neck Dissection
por: Veenstra, Hidde J., et al.
Publicado: (2012)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

ASO Author Reflections: The MelFo-Study, UK: Effects of a Reduced Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma IB–IIC Patients After 3 Years
por: Moncrieff, Marc, et al.
Publicado: (2020)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
por: Wade, Ryckie G., et al.
Publicado: (2018)

MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma
por: Spraker, Matthew B., et al.
Publicado: (2019)

The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with In-transit Melanoma Metastases Treated with Isolated Limb Perfusion
por: Katsarelias, Dimitrios, et al.
Publicado: (2018)

Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement
por: Deckers, Eric A, et al.
Publicado: (2020)

Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized?: A Retrospective, Multicenter Cohort Study
por: Oude Ophuis, C. M. C., et al.
Publicado: (2015)

Letter in reply: increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement
por: Deckers, Eric A, et al.
Publicado: (2020)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Erratum to: S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
por: Kruijff, S., et al.
Publicado: (2010)

Sorting Through the Heterogeneity of Recurrent Melanoma
por: Jacobs, Lisa K., et al.
Publicado: (2008)

Worse Survival in Elderly Patients with Extremity Soft-Tissue Sarcoma
por: Hoven-Gondrie, Miriam L., et al.
Publicado: (2016)

ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified
por: Francken, Anne Brecht, et al.
Publicado: (2019)

Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
por: Esposito, Andrew, et al.
Publicado: (2021)

Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma
por: El Sharouni, Mary-Ann, et al.
Publicado: (2019)

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
por: Davis, Catherine H., et al.
Publicado: (2021)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8oklrlbua90a77e8jts8aj3de6